Introduction {#S1}
============

Restoring penumbral perfusion is the key target of therapeutic efforts in acute ischemic stroke. The penumbra is characterized by reduced perfusion with functional impairment but without immediate irreversible damage ([@B1], [@B2]). So far, in cases of insufficient or unsuccessful vessel recanalization, maintaining normal to higher mean arterial pressure (MAP) is the goal to preserve penumbral perfusion. MAP is expected to be related to cerebral perfusion (CP), as constant cerebral blood flow (CBF) is maintained over a wide range of MAP due to vessel autoregulation ([@B3]).

Furthermore, MAP is expected to correlate with cardiac output (CO), since MAP is the product of CO and systemic vascular resistance \[SVR; ([@B4])\]. In order to increase MAP, CO according to the Frank-Starling curve and SVR are enhanced *via* fluid and/or catecholamine administration ([@B5]). Former studies have demonstrated that MAP levels' correlation to CO are volume state dependent, and thus CO might be a better parameter to focus on ([@B4]--[@B6]) since CBF depends on CO rather than on MAP in areas with impaired autoregulation ([@B7]). Further influencing factors may change CO levels, for example, atrial fibrillation or medication ([@B8]).

We therefore hypothesized that CP, assessed at bedside *via* perfusion ultrasound, depends on CO as a systemic parameter of organ perfusion rather than on MAP.

Materials and Methods {#S2}
=====================

Subjects {#S2-1}
--------

Ten consecutive patients admitted to the Neurological Intensive Care Unit of University Hospital in Freiburg who were diagnosed with large ischemic stroke of the middle cerebral artery (MCA) territory *via* CT or MRI were included in this observational, prospective pilot study. Patients with other intracerebral lesions, known severe CO failure, and allergy to sonographic contrast were excluded. For clinical status and follow-up, patients' symptom severity was assessed *via* the National Institute of Health Stroke Scale (NIHSS) and the modified Rankin Scale (mRS) on admission and at discharge. Additional to standard monitoring, all patients received an advanced hemodynamic monitoring with the parameters described below. Following hemodynamic baseline measurements, all patients received transcranial color-coded duplex sonography (TCCD) and transcranial perfusion sonography (TPS) according to a standardized protocol. Hemodynamic parameters then were optimized according to the target MAP and cardiac index (CI)-levels. Sonographic measurement was repeated after normalizing hemodynamic levels.

Hemodynamic Assessment and Therapeutic Measures {#S2-2}
-----------------------------------------------

As part of the in-house standard protocol for patients with large stroke, all patients received advanced cardiac monitoring either with a Vigileo- or a PiCCO-hemodynamic monitoring system (Flotrac-System, Edwards Lifesciences, USA; Pulsion Medical System, Germany) besides standard hemodynamic monitoring of heart frequency and MAP. These monitoring systems perform an analysis of the arterial pulse contour and calculate the CI (index results from CO and stroke volume related to body surface). Further monitoring parameters are the stroke volume variance (SVV; a dynamic parameter that reflects intravasal volume status) and the SVR-index \[SVRI; a parameter identifying constriction or relaxation of systemic vasculature; ([@B4])\]. MAP levels of ≥70 mmHg and CI ranging between ≥3.0 and ≤4.5 were targeted. In patients with MAP \< 70 mmHg or CI \< 3.0, crystalloids should be administered as a first step until SVV \< 10%. If this measure does not increase the hemodynamic parameters, noradrenaline, a peripheral vasoconstrictor, according to SVRI levels should be used. Dobutamine, as a positive inotropic substance, can be used as a last option in order to increase CI.

Transcranial Sonography {#S2-3}
-----------------------

### Transcranial Color-Coded Duplex Sonography {#S2-3-1}

Intracranial vascular status was assessed with a GE Logique 7 expert system (GE Healthcare, USA) using a 2 MHz-transducer focusing on the transtemporal approach in a meato-orbital plane. Mean MCA velocity (MCAv) was registered to determine the vessel recanalization status as well as perfusion status according to Doppler flow velocity.

### Transcranial Perfusion Sonography {#S2-3-2}

Transcranial perfusion sonography was performed bilaterally in the axial thalamic plane. For TPS, a harmonic mode with coded pulse inversion sequences was used (Pulsed sequences at 2 MHz and detection at 3 MHz, mechanical index 1.1--1.3, gain and transmit power was optimized individually in each patient, frame rate 1 Hz). Performance of TPS relied on the application ultrasound contrast media SonoVue (Bracco^®^), which consists of microbubbles containing sulfohexaflourane gas and coated with a phospholipid shell. To evaluate CP, we used a bolus-kinetic method with a high mechanical index, which aims to destroy the injected microbubbles that have entered microcirculation and lie in the field of the ultrasound beam. Time-triggered cineloops (45 s) of the cerebral image in the thalamic plane were obtained with an image frame rate of 1/1,000 ms. The resulting signals obtained over time represent time--intensity curves of ultrasound contrast media within the microcirculation and thus may detect regions of lacking or showing slowed CP. Obtained cineloops were then stored on an external work station for further offline analysis. For offline analysis, regions of interest (ROI) within the affected as well as the non-affected hemisphere were defined in the cortex, thalamus, and the basal ganglia. Time-to-peak (TTP) curves of the contrast media within the ROI were derived as surrogate marker of the CP and used for further analysis.

Statistics {#S2-4}
----------

Obtained TTP data as well as MCAv were correlated with hemodynamic parameters (data at baseline and after optimizing hemodynamics). Continuous data was analyzed *via* Student's *t*-test or Mann--Whitney *U* test according to the distribution level. Pearson's correlation analyses were performed in order to reveal correlations of CI and MAP levels on one side and TTP and MCAv on the other side. Statistics were performed using IBM SPSS statistics 21 software.

Results {#S3}
=======

Patients' characteristics are outlined in Table [1](#T1){ref-type="table"}. NIHSS levels did not change significantly from admission status (median 15.5 points) to time of discharge (median 16 points). mRS levels were stable (median 5.0 on admission and at discharge; three patients had died). Only four patients were admitted with an observed point of time of symptom onset (mean 153.5 ± 117.3 min before admission). The other six patients suffered from wake-up strokes. Hemodynamic monitoring was performed for 152.1 (± 128.9) h. It took 2.75 ± 5.9 h to optimize CI and until the second performance of TPS. When hemodynamics were optimized, MAP levels ranged from 73 to 110 mmHg and CI levels between 2.1 and 5.9. There was only one patient with atrial fibrillation as a possible influencing factor on CO but the patient showed constant optimal CI levels that did not make hemodynamic measures necessary. For optimizing CI levels, two patients received a volume challenge and additional inotropic therapy, two patients received singular volume challenge, and one patient received inotropic therapy alone. All other patients had no need for further therapeutic intervention concerning systemic hemodynamics.

###### 

Patients' characteristics.

  Patient number   Age (years)   Gender   Vessel occlusion   Side        Treatment    Atrial fibrillation   Infarction etiology
  ---------------- ------------- -------- ------------------ ----------- ------------ --------------------- ---------------------
  1                64            Male     MCA + PCA          Right       None         No                    Unknown
  2                70            Male     ICA + MCA          Left        None         No                    Atherosclerosis
  3                60            Female   MCA + ACA          Bilateral   None         No                    Other
  4                45            Male     ICA + MCA + ACA    Right       IV-T         No                    Other
  5                46            Male     ICA + MCA + ACA    Right       None         No                    Unknown
  6                25            Female   MCA                Left        IV-T + EVT   No                    Unknown
  7                74            Male     MCA                Right       None         Yes                   Cardioembolism
  8                58            Male     ICA + MCA          Right       None         No                    Unknown
  9                54            Male     MCA                Left        None         No                    Atherosclerosis
  10               73            Female   None               Bilateral   None         No                    Cardioembolism

*Vessel occlusion: internal carotid artery (ICA), middle cerebral artery (MCA), anterior cerebral artery (ACA), posterior cerebral artery (PCA); treatment: intravenous thrombolysis (IV-T), endovascular treatment (EVT); infarction etiology according to Trial of Org 10172 in Acute Stroke Treatment-criteria ([@B9])*.

Correlation analyses of hemodynamic (at baseline and after optimization) and sonographic parameters showed various aspects: analyses of CI and MAP levels, TTP and MCAv revealed highly significant inverse correlations of CI and TTP in the affected and unaffected basal ganglia with *r* = −0.798 (*p* \< 0.001) and *r* = −0.893 (*p* \< 0.0001), respectively. In none of the patients, sufficient perfusion curves of the affected cortex could be obtained. No correlation was found for TTP with MAP (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}).

![Correlations of cardiac index (CI) and mean arterial pressure (MAP) levels and time-to-peak (TTP) values. **(A)** Inverse correlation of CI and TTP in affected basal ganglia (*r* = −0.798, *p* \< 0.001). **(B)** Inverse correlation of CI and TTP in unaffected basal ganglia (*r* = −0.893, *p* \< 0.0001). **(C)** No significant correlation of MAP and affected basal ganglia (*r* = −0.044, *p* = 0.911). **(D)** No significant correlation of MAP and unaffected basal ganglia (*r* = 0.202, *p* = 0.575).](fneur-08-00706-g001){#F1}

![Transcranial perfusion sonography (example taken from patient 2). **(A)** Baseline measurement \[before optimization of cardiac index (CI)\] at CI 2.1 and mean arterial pressure (MAP) 89 mmHg. **(B)** Second measurement (after optimization of CI) at CI 3.45 and MAP 89 mmHg.](fneur-08-00706-g002){#F2}

No significant correlation of MCAv with CI (*r* = 0.552, *p* = 0.123) or MAP (*r* = −0.591, *p* = 0.094) was detected.

Discussion {#S4}
==========

The results of this prospective pilot study challenge the current state of the art guiding hemodynamic therapy by MAP levels since they demonstrate that CP can rather be improved by CO-guided than MAP-focused hemodynamic therapy.

In healthy subjects, CBF is maintained constant independently of blood pressure changes by cerebral autoregulation ([@B10]). However, in acute stroke, autoregulation is injured in the ischemic and penumbral area, and furthermore, patients may suffer from global autoregulatory dysfunction ([@B3], [@B11]). The changes in MAP may lead to penumbral hypo- or hyperperfusion ([@B10]). Maintaining particularly penumbral perfusion in order to reduce the final infarction volume is thus the focus of therapeutic measures in stroke patients. Consequently, early penumbral reperfusion leads to improved patient outcomes ([@B1]).

Mean arterial pressure is the most widely used routine monitoring parameter in stroke ([@B3], [@B12]). Interestingly, in ischemic dysregulated areas, CP also depends on CO ([@B7]). Furthermore, physiological background claims organ oxygen delivery depending on CO ([@B13]). As the correlation of MAP and CO is volume state dependent, focusing on MAP in order to improve perfusion and oxygen delivery may hold true only in the isovolemic state ([@B5], [@B6]). Our preliminary data show that correlation of CP measured by the surrogate marker of TTP times examined by TPS with MAP is only moderate and not significant within the present sample size. Thus, optimizing MAP not necessarily implicates improvement of perfusion, and our data suggest CP being rather dependent on CO since we could demonstrate inverse correlation of TTP times with CO.

A preclinical trial with rats supports the implication as change of MAP by administration of phenylephrine showed no effect on infarction size or final functional outcome ([@B14]). Furthermore, other studies have shown a CO-dependent increase of CP in patients with subarachnoid hemorrhage ([@B15]). Various experimental interventions intending a shift of blood volume lead to a significant higher perfusion in rats with MCA-occlusion ([@B14]) and humans ([@B5]). Also, volume substitution lead to CO changes leaving MAP levels constant and secondary increased CP ([@B15], [@B16]).

The results of the present study should be regarded as preliminary due to its low patient number. We also did not apply quantitative radiographic methods for estimation of focal perfusion. Yet, TCCD has been found to be a reliable method to detect intracranial arterial pathologies before ([@B17]), and TPS is a sufficient technique to display infarction core and hypoperfused tissue at risk in ischemic strokes ([@B18]). Moreover, it could be performed at bedside in these critically ill patients.

We conclude that CO-dependent changes of CP may be more relevant than MAP-guided hemodynamic therapy in ischemic stroke patients in order to maintain and optimize cerebral penumbral perfusion. The clinical benefit of CO-guided therapy needs to be proven in further clinical trials.
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